Novavax, Inc. (NVAX) Guidance & Earnings Results

On 2026-08-06 Novavax, Inc. raised guidance: "Revenue framework raised to $235M-$275M; combined R&D and SG&A expense guidance improved by $10M at…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

NVAXNovavax, Inc.Follow NVAX — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 1.6B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 5 Nov, in 12 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
6 Aug 26	Raised	Revenue framework raised to $235M-$275M; combined R&D and SG&A expense guidance improved by $10M at midpoint · full year
6 May 26	Reaffirmed	Reiterates 2026 Revenue Framework and Combined R&D and SG&A expense guidance · full year
26 Feb 26	Raised	Non-GAAP R&D and SG&A targets lowered: $325M for 2026, $225M for 2027, $200M for 2028 · full year
6 Nov 25	Raised	Raises Full Year 2025 Revenue Framework · full year
6 Aug 25	Raised	FY2025 Adjusted Total Revenue raised to $1,000-1,050M from $975-1,025M; Combined R&D and SG&A expenses guidance raised to $495-545M from $475-525M · full year

Novavax, Inc. — questions

What guidance did Novavax, Inc. give?: On 2026-08-06: "Revenue framework raised to $235M-$275M; combined R&D and SG&A expense guidance improved by $10M at midpoint"
When does Novavax, Inc. report earnings?: Novavax, Inc.'s next earnings report is expected on 2026-11-05.

Every figure on this page comes from Novavax, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.